Company intelligence / Profile preview

DRI Bioscience

Miami, Florida, United States

Ownership: Private
Development stage: Other

Overview

DRI Bioscience is a pre-clinical stage biotechnology company focused on developing novel small molecule therapeutics for the treatment of refractory cancers. The company's lead research programs target the hypoxia-inducible factor (HIF) pathway, which plays a critical role in tumor survival, angiogenesis, and resistance to conventional therapies. By inhibiting these pathways, DRI Bioscience aims to disrupt the tumor microenvironment and improve outcomes for patients with aggressive solid tumors such as glioblastoma and pancreatic cancer. The company is currently advancing its lead candidates through lead optimization and early safety studies.

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Biotech

Drug pipeline

1 asset

ACT01

Unknown

Beyond the preview

Go deeper on DRI Bioscience.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DRI Bioscience.

Explore the full profile